IP Library Granted Patent US 11,389,502
Granted Patent B2
US 11,389,502 · App. 16/332,926 · Granted Jul 19, 2022

Cell modulation

Inventors: Helen Connaris (St. Andrews, GB); Judith Telford (St. Andrews, GB); Graeme Rogers (St. Andrews, GB)
Assignee: OMIDEON LIMITED
A61K38/164A61K38/178A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,502
App. No.
16/332,926
Granted
Jul 19, 2022
Kind
B2
Abstract

The present disclosure provides molecules which modulate cell growth. These molecules include those that bind sialic acid which may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.

Claims (9)

1. A method of treating cancer, said method comprising administering a sialic acid binding molecule to a subject in need thereof, wherein the sialic acid binding molecule is a multimeric carbohydrate binding module (CBM).

2. The method of claim 1 , wherein the cancer is lung cancer, cervical cancer, colon cancer and/or breast cancer.

3. The method of claim 1 , wherein the multimeric carbohydrate binding module comprises one or more family 40 carbohydrate binding module(s).

4. The method of claim 1 , wherein the multimeric carbohydrate binding module comprises a sialic acid binding domain of Vibrio cholerae NanH sialidase and/or a sialic acid binding domain of Streptococcus pneumoniae NanA sialidase.

5. The method of claim 4 , wherein the Vibrio cholerae NanH sialidase comprises the amino acid sequence of SEQ ID NO: 1 or 2.

6. The method of claim 4 , wherein the Streptococcus pneumoniae NanA sialidase comprises the amino acid sequence of SEQ ID NO: 3 or 4.

7. The method of claim 1 , wherein the multimeric CBM comprises two or more sialic acid binding domains of Vibrio cholerae NanH sialidases and/or two or more sialic acid binding domains of Streptococcus pneumoniae NanA sialidases.

8. The method of claim 1 , wherein the multimeric CBM comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 sialic acid binding domains of Vibrio cholerae NanH sialidases and/or Streptococcus pneumoniae NanA sialidases.

9. The method of claim 1 , wherein the multimeric CBM is a combination of four sialic acid binding domains of Vibrio cholerae NanH sialidase (Vc4CBM), a combination of two sialic acid binding domains of Vibrio cholerae NanH sialidase and a trimerisation domain (Vc2CBMTD), and/or a combination of two sialic acid binding domains of Streptococcus pneumoniae NanA sialidase and a trimerisation domain (Sp2CBMTD).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: CONNARIS, HELEN; TELFORD, JUDITH; ROGERS, GRAEME
To: UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Reel/Frame 056483/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
To: PNEUMAGEN LIMITED
Reel/Frame 056484/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: PNEUMAGEN LIMITED
To: PNEUMAGEN (HOLDINGS) LIMITED
Reel/Frame 056484/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: PNEUMAGEN (HOLDINGS) LIMITED
To: OMIDEON LIMITED
Reel/Frame 056484/0563 →
Priority Claims (1)
GB 1616006 · Sep 20, 2016 · national
Continuity (1)
Related Publication 20190247460A1 · Aug 15, 2019